Literature DB >> 17372273

EGFRvIII escapes down-regulation due to impaired internalization and sorting to lysosomes.

Michael V Grandal1, Roza Zandi, Mikkel W Pedersen, Berthe M Willumsen, Bo van Deurs, Hans S Poulsen.   

Abstract

EGFRvIII is a mutant variant of the epidermal growth factor receptor (EGFR) found exclusively in various cancer types. EGFRvIII lacks a large part of the extracellular domain and is unable to bind ligands; however, the receptor is constitutively phosphorylated and able to activate downstream signaling pathways. Failure to attenuate signaling by receptor down-regulation could be one of the major mechanisms by which EGFRvIII becomes oncogenic. Using a cell system expressing either EGFR or EGFRvIII with no expression of other EGFR family members and with endogenous levels of key degradation proteins, we have investigated the down-regulation of EGFRvIII and compared it to that of EGFR. We show that, in contrast to EGFR, EGFRvIII is inefficiently degraded. EGFRvIII is internalized, but the internalization rate of the mutated receptor is significantly less than that of unstimulated EGFR. Moreover, internalized EGFRvIII is recycled rather than delivered to lysosomes. EGFRvIII binds the ubiquitin ligase c-Cbl via Grb2, whereas binding via phosphorylated tyrosine residue 1045 seems to be limited. Despite c-Cbl binding, the receptor fails to become effectively ubiquitinylated. Thus, our results suggest that the long lifetime of EGFRvIII is caused by inefficient internalization and impaired sorting to lysosomes due to lack of effective ubiquitinylation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17372273     DOI: 10.1093/carcin/bgm058

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  54 in total

1.  Glioblastoma-derived epidermal growth factor receptor carboxyl-terminal deletion mutants are transforming and are sensitive to EGFR-directed therapies.

Authors:  Jeonghee Cho; Sandra Pastorino; Qing Zeng; Xiaoyin Xu; William Johnson; Scott Vandenberg; Roel Verhaak; Andrew D Cherniack; Hideo Watanabe; Amit Dutt; Jihyun Kwon; Ying S Chao; Robert C Onofrio; Derek Chiang; Yuki Yuza; Santosh Kesari; Matthew Meyerson
Journal:  Cancer Res       Date:  2011-10-14       Impact factor: 12.701

2.  Mig-6 controls EGFR trafficking and suppresses gliomagenesis.

Authors:  Haoqiang Ying; Hongwu Zheng; Kenneth Scott; Ruprecht Wiedemeyer; Haiyan Yan; Carol Lim; Joseph Huang; Sabin Dhakal; Elena Ivanova; Yonghong Xiao; Hailei Zhang; Jian Hu; Jayne M Stommel; Michelle A Lee; An-Jou Chen; Ji-Hye Paik; Oreste Segatto; Cameron Brennan; Lisa A Elferink; Y Alan Wang; Lynda Chin; Ronald A DePinho
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-29       Impact factor: 11.205

3.  Multivariate signaling regulation by SHP2 differentially controls proliferation and therapeutic response in glioma cells.

Authors:  Christopher M Furcht; Janine M Buonato; Nicolas Skuli; Lijoy K Mathew; Andrés R Muñoz Rojas; M Celeste Simon; Matthew J Lazzara
Journal:  J Cell Sci       Date:  2014-06-20       Impact factor: 5.285

4.  A direct role for Met endocytosis in tumorigenesis.

Authors:  Carine Joffre; Rachel Barrow; Ludovic Ménard; Véronique Calleja; Ian R Hart; Stéphanie Kermorgant
Journal:  Nat Cell Biol       Date:  2011-06-05       Impact factor: 28.824

5.  Dynamin2 downregulation delays EGFR endocytic trafficking and promotes EGFR signaling and invasion in hepatocellular carcinoma.

Authors:  Chaojie Gong; Jubo Zhang; Lan Zhang; Yingcong Wang; Hui Ma; Weizhong Wu; Jiefeng Cui; Yanhong Wang; Zhenggang Ren
Journal:  Am J Cancer Res       Date:  2015-01-15       Impact factor: 6.166

6.  EGFRvIII-Stat5 Signaling Enhances Glioblastoma Cell Migration and Survival.

Authors:  Alison Roos; Harshil D Dhruv; Sen Peng; Landon J Inge; Serdar Tuncali; Michael Pineda; Nghia Millard; Zachary Mayo; Jennifer M Eschbacher; Joseph C Loftus; Jeffrey A Winkles; Nhan L Tran
Journal:  Mol Cancer Res       Date:  2018-05-03       Impact factor: 5.852

7.  Disrupted RabGAP function of the p85 subunit of phosphatidylinositol 3-kinase results in cell transformation.

Authors:  M Dean Chamberlain; Tim Chan; Jennifer C Oberg; Andrea D Hawrysh; Kristy M James; Anurag Saxena; Jim Xiang; Deborah H Anderson
Journal:  J Biol Chem       Date:  2008-04-03       Impact factor: 5.157

Review 8.  Endocytosis and cancer.

Authors:  Ira Mellman; Yosef Yarden
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-12-01       Impact factor: 10.005

9.  Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members.

Authors:  D L Wheeler; S Huang; T J Kruser; M M Nechrebecki; E A Armstrong; S Benavente; V Gondi; K-T Hsu; P M Harari
Journal:  Oncogene       Date:  2008-02-25       Impact factor: 9.867

10.  Activity and cellular localization of an oncogenic glioblastoma multiforme-associated EGF receptor mutant possessing a duplicated kinase domain.

Authors:  B H Ozer; G J Wiepz; P J Bertics
Journal:  Oncogene       Date:  2009-11-16       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.